Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Abajo, A. (Ana) | - |
dc.creator | Rodriguez, J. (Javier) | - |
dc.creator | Bitarte, N. (Nerea) | - |
dc.creator | Zarate, R. (Ruth) | - |
dc.creator | Boni, V. (Valentina) | - |
dc.creator | Ponz-Sarvise, M. (Mariano) | - |
dc.creator | Chopitea, A. (Ana) | - |
dc.creator | Bandres, E. (Eva) | - |
dc.creator | Garcia-Foncillas, J. (Jesús) | - |
dc.date.accessioned | 2014-08-23T11:03:54Z | - |
dc.date.available | 2014-08-23T11:03:54Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Abajo A, Rodríguez J, Bitarte N, Zarate R, Boni V, Ponz M, et al. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer. 2010 Nov 9;103(10):1529-1535 | es_ES |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://hdl.handle.net/10171/36370 | - |
dc.description.abstract | BACKGROUND: To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional gemcitabine (FDR-GMB) and bevacizumab in pretreated metastatic colorectal cancer (mCRC) patients. Pharmacogenomic analysis was performed to investigate the association between VEGF single-nucleotide polymorphisms and clinical outcome. PATIENTS AND METHODS: A total of 89 mCRC patients were recruited in a two-step study design; 28 were included in the dose-finding study and 59 in the pharmacogenomic analysis. The FDR-GMB of 1000 mg m⁻², bevacizumab 5 mg kg⁻¹ and CPT-11 doses ranging from 100 to 160 mg m⁻² were explored. The VEGF protein serum levels were quantified by EIA. Allelic discrimination was performed to genotype polymorphisms in the VEGF gene. RESULTS: CPT-11 RD was 150 mg m⁻². Diarrhoea and neutropenia were the DLT. After a median follow-up of 42 months, the median time to progression (TTP) and overall survival were 5.2 and 19.9 months, respectively. VEGF levels were significantly correlated with VEGF-2578AA and VEGF-460CC genotypes, and a trend was observed with VEGF+405GG genotype. The presence of any of these genotypes correlated with a longer median TTP (8.8 vs 4.5 months, P=0.04). CONCLUSION: The triplet combination tested in this study is effective and well tolerated. A possible predictive role for VEGF gene polymorphisms and baseline VEGF circulating levels is suggested. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Cancer Research UK | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Antibodies, Monoclonal | es_ES |
dc.subject | Bevacizumab | es_ES |
dc.subject | Irinotecan | es_ES |
dc.subject | Gemcitabine | es_ES |
dc.subject | Colorectal Neoplasms/pathology | es_ES |
dc.title | Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1038/sj.bjc.6605908 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.